Physician
Palo Verde Hematology Oncology LTD.
Palo Verde Hematology Oncology LTD. was paid $17.10M by Medicaid between Jan 2018 and Dec 2024, across 99 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 24% of everything it billed.
33Billing provider infoPALO VERDE HEMATOLOGY ONCOLOGY LTD.
GLENDALE, AZ 85304
GLENDALE, AZ 85304
33aNPI1447272372assigned 07/23/2006
33bProvider typeHematology & Oncology Physician
28Total paid$17.10M
24GClaims400,994
24DCodes billed99
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in Arizona
Rank by total paid#1 of 7
Median peer was paid$68K
This provider vs. median250×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 67,991 | $3.29M | |
| 2019 | 69,481 | $3.82M | |
| 2020 | 58,505 | $2.41M | |
| 2021 | 58,970 | $2.31M | |
| 2022 | 51,171 | $1.83M | |
| 2023 | 51,225 | $1.85M | |
| 2024incomplete | 43,651 | $1.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 78,087 | 71,022 | $4.14M |
| J2505 | Injection, pegfilgrastim, 6 mg | 11% | 628 | 423 | $1.90M |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 8.0% | 7,040 | 1,727 | $1.37M |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 6.3% | 16,372 | 6,622 | $1.07M |
| 52000 | 5.8% | 7,393 | 7,075 | $985K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.5% | 10,848 | 10,576 | $941K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 5.3% | 11,554 | 6,253 | $909K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.0% | 22,530 | 21,250 | $852K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 4.8% | 10,918 | 9,082 | $818K |
| 77014 | 3.6% | 9,808 | 2,603 | $610K | |
| 99205 | Prolong outpt/office vis | 2.6% | 4,036 | 3,933 | $450K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1.6% | 2,990 | 1,336 | $280K |
87 more codes
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.5% | 1,825 | $257K |
| 99223 | Prolong inpt eval add15 m | 1.3% | 2,028 | $225K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 4,483 | $214K |
| 99232 | Hospital visit by a doctor, follow-up day | 1.1% | 4,268 | $193K |
| 51798 | 1.1% | 26,040 | $191K | |
| 96367 | 1.0% | 7,769 | $175K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,604 | $127K |
| 81002 | <1% | 59,115 | $127K | |
| 31231 | <1% | 796 | $113K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 37,296 | $84K |
| 77427 | <1% | 796 | $83K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,864 | $68K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 116 | $66K |
| 77336 | <1% | 1,376 | $62K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,694 | $55K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 292 | $42K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 287 | $38K |
| 51729 | <1% | 136 | $37K | |
| 99243 | <1% | 449 | $37K | |
| 76775 | <1% | 1,476 | $35K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 532 | $32K |
| 30140 | <1% | 249 | $30K | |
| 92557 | <1% | 1,006 | $27K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 342 | $27K |
| 51741 | <1% | 5,257 | $26K | |
| 51797 | <1% | 274 | $26K | |
| 51728 | <1% | 147 | $24K | |
| 87799 | <1% | 278 | $20K | |
| 31237 | <1% | 70 | $20K | |
| 31579 | <1% | 140 | $17K | |
| 99254 | <1% | 131 | $15K | |
| 51792 | <1% | 64 | $15K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 12 | $15K |
| 92567 | <1% | 1,337 | $14K | |
| 96417 | <1% | 240 | $13K | |
| 87492 | <1% | 288 | $12K | |
| 87652 | <1% | 310 | $11K | |
| 87512 | <1% | 298 | $11K | |
| 87592 | <1% | 289 | $10K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 9,992 | $9K |
| 87500 | <1% | 286 | $9K | |
| 87641 | <1% | 277 | $8K | |
| 96411 | <1% | 175 | $8K | |
| 87653 | <1% | 282 | $8K | |
| 76857 | <1% | 555 | $8K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 23 | $7K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 62 | $7K |
| 87481 | <1% | 265 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 283 | $7K |
| 87640 | <1% | 248 | $7K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 31 | $6K |
| 52332 | <1% | 76 | $6K | |
| 51784 | <1% | 295 | $6K | |
| 74420 | <1% | 373 | $6K | |
| 50590 | <1% | 14 | $5K | |
| 52224 | <1% | 15 | $5K | |
| 96415 | <1% | 219 | $5K | |
| 99459 | <1% | 384 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,433 | $4K |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 3,946 | $4K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 95 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 110 | $4K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 15 | $3K |
| 99253 | <1% | 34 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 125 | $2K |
| 77334 | <1% | 20 | $2K | |
| 70486 | <1% | 31 | $2K | |
| 51701 | <1% | 61 | $2K | |
| 99442 | <1% | 101 | $1K | |
| 96409 | <1% | 19 | $1K | |
| 96523 | <1% | 65 | $1K | |
| 88313 | <1% | 37 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,182 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 38 | $945.95 |
| G6002 | Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy | <1% | 18 | $871.41 |
| 51700 | <1% | 12 | $670.77 | |
| 96368 | <1% | 41 | $525.50 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 541 | $469.08 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 16 | $407.84 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 36 | $393.48 |
| 82728 | <1% | 39 | $383.73 | |
| 93793 | <1% | 59 | $240.08 | |
| 85610 | <1% | 115 | $239.96 | |
| 96377 | <1% | 17 | $235.60 | |
| 96402 | <1% | 13 | $197.00 | |
| J2704 | Injection, propofol, 10 mg | <1% | 40 | $142.79 |
| A4550 | Surgical trays | <1% | 702 | $50.10 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRATZLAFF, LYNN (CFO/COO)